Quadrant Biosciences
Quadrant Biosciences was a Syracuse, NY-based epigenetic diagnostics company that developed autism screening technology for early detection of neurological disorders in children; the company has since filed for bankruptcy and ceased operations.
- Company typePrivate
- Founded2015
- HeadquartersSyracuse, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
Quadrant Biosciences firmographics
Firmographics- Name
- Quadrant Biosciences
- Website
- https://quadrantbiosciences.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Closed
- Headcount range
- 51–100 employees
- Short description
- Quadrant Biosciences was a Syracuse, NY-based epigenetic diagnostics company that developed autism screening technology for early detection of neurological disorders in children; the company has since filed for bankruptcy and ceased operations.
- Ownership category
- akta.pro rank
Quadrant Biosciences industry classification
Industry- Product category
- Epigenetic Diagnostics
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
- akta.pro secondary industries
- Epigenomics & Chromatin Profiling Services (HLAGANAF), Autism Diagnostic & Educational Assessment Services (EDAKAKAA)
Keywords
Where Quadrant Biosciences is headquartered
LocationHeadquarters
- HQ city
- Syracuse
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Quadrant Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Quadrant Biosciences product offering
Product offeringCore offering
Quadrant Biosciences developed epigenetic diagnostic tests focused on the early detection of neurological disorders, with autism screening as its primary use case. The company operated a CLIA-certified clinical laboratory and processed saliva-based samples to generate screening insights for healthcare providers. Its offering combined proprietary epigenetic biomarker analysis with clinical laboratory services.
Differentiator
Problem solved
Functional benefit
Products and services
- Autism Screening Service (Epigenetic Diagnostic) Clinical laboratory-based epigenetic diagnostic screening service for early detection of neurological disorders (with autism screening as the primary use case), delivered through a CLIA-certified laboratory and processed via saliva-based sample analysis for healthcare providers and patients.
Companies that use Quadrant Biosciences
Customer profileSegments1 record
Ideal customer profiles2 records
Quadrant Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Quadrant Biosciences partnerships and signals
Strategic signalScale indicators1 record
Quadrant Biosciences competitors and assessment
Company assessmentDirect peers
- Lineagen: Pediatric diagnostics company historically focused on genetic and epigenetic testing for autism spectrum disorder and other neurodevelopmental conditions, making it the closest like-for-like competitor to Quadrant's autism screening offering.
Broad incumbents
- Myriad Genetics: Established molecular diagnostics company offering genetic and genomic tests across multiple therapeutic areas; provides a benchmark for CLIA-validated DNA/RNA-based testing infrastructure and reimbursement strategy similar to what Quadrant pursued.
- Natera: Public molecular diagnostics company specializing in cell-free DNA and broader genetic testing; comparable on operating a proprietary CLIA lab, assay development pipeline, and pediatric/oncology screening commercial model.
- Quest Diagnostics: Large reference laboratory offering extensive neurodevelopmental and pediatric testing services including autism-related diagnostics; sets the bar for national distribution and payer contracts that a startup epigenetic diagnostics company would need to match.
- Laboratory Corporation of America (Labcorp): National clinical reference lab with a broad molecular and genetic diagnostics menu, including pediatric and neurological testing, and provides a benchmark for operational scale and reimbursement relationships relevant to Quadrant's CLIA-based business.
Emerging players
- GeneDx: Clinical genetic testing company now part of the BioReference network, focused on rare disease and pediatric genomic diagnostics; overlaps with Quadrant in pediatric neurology-oriented testing channels and the build-out of high-complexity CLIA assays.
- Sophia Genetics: Data-driven genomic and clinical analytics company used by hospitals and labs for genomic testing workflows; comparable as a peer leveraging software and analytics layers on top of molecular diagnostic assays for clinical decision-making.
Regional players
- ARUP Laboratories: Academic-affiliated reference laboratory with deep neurology and genetics test menus; comparable on operating a CLIA-certified lab serving pediatric and academic medical center customers who order autism and related neurodevelopmental workups.
Others
- Bio-Rad Laboratories: Life science tools and clinical diagnostics manufacturer whose molecular and quality-control products are used by labs like Quadrant's; relevant as an infrastructure/upstream peer rather than a direct testing competitor.
- PerkinElmer: Diagnostics and life sciences company offering genetic screening, newborn screening, and laboratory instruments; comparable as an incumbent in the epigenetic/genetic testing stack and laboratory automation Quadrant would have relied on.
Market position
Customer concentration
Quadrant Biosciences social profiles
Digital presenceQuadrant Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Quadrant Biosciences leadership team
Management profileNumber of profiles
Profiles5 records
Quadrant Biosciences funding detail
Funding detailFunding overview
Funding rounds5 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Quadrant Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Quadrant Biosciences
What does Quadrant Biosciences do?
Quadrant Biosciences developed epigenetic diagnostic tests focused on the early detection of neurological disorders, with autism screening as its primary use case. The company operated a CLIA-certified clinical laboratory and processed saliva-based samples to generate screening insights for healthcare providers. Its offering combined proprietary epigenetic biomarker analysis with clinical laboratory services.
Is Quadrant Biosciences a public or private company?
Quadrant Biosciences is a private company. It is classified as venture growth investor backed and is currently closed.
When was Quadrant Biosciences founded?
Quadrant Biosciences was founded in 2015. It employs 51 to 100 people.
Where is Quadrant Biosciences based?
Quadrant Biosciences is headquartered in Syracuse, United States, in the North America region.
Who are Quadrant Biosciences's main competitors?
Lineagen is listed as a direct peer. Broad incumbents are Myriad Genetics, Natera, Quest Diagnostics and Laboratory Corporation of America (Labcorp). Emerging players are GeneDx and Sophia Genetics. ARUP Laboratories is listed as a regional player. Others are Bio-Rad Laboratories and PerkinElmer.
Does Quadrant Biosciences have an API?
No public API is recorded for Quadrant Biosciences.
What industry is Quadrant Biosciences in?
Quadrant Biosciences's product category is Epigenetic Diagnostics. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays), with a secondary code of HLAGANAF, Epigenomics & Chromatin Profiling Services. Its NAICS code is 621511 and its SIC code is 8071.